UnknownPhase 1NCT04709458

Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis

Studying Acute panmyelosis with myelofibrosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Taiga Biotechnologies, Inc.
Principal Investigator
Andrea Bacigalupo, MD
Unit for Hematology and BMT, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy
Intervention
TBX-2400(biological)
Enrollment
10 enrolled
Eligibility
18 years · All sexes
Timeline
2022 – 2024

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04709458 on ClinicalTrials.gov

Other trials for Acute panmyelosis with myelofibrosis

Additional recruiting or active studies for the same condition.

See all trials for Acute panmyelosis with myelofibrosis →

← Back to all trials